ANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection

(RTTNews) - ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response or "DDR" assay for the detection of micronuclei in circulating tumour cells as a measure of DDR. https://www.nasdaq.com/articles/angle-reaches-deal-with-astrazeneca-to-advance-ddr-assay-for-circulating-tumor-cell